<DOC>
	<DOCNO>NCT01907165</DOCNO>
	<brief_summary>This clinical trial study disulfiram treat patient glioblastoma multiforme ( GBM ) complete radiation therapy temozolomide . Disulfiram may block enzyme need tumor cell growth improve clinical outcome GBM patient .</brief_summary>
	<brief_title>Disulfiram Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Disulfiram</mesh_term>
	<criteria>Diagnosis histologically confirm GBM ( WHO grade IV ) . At least 18 year age . ECOG performance status least 2 . Has receive process complete course definitive radiotherapy least 45 Gy concurrent temozolomide ( patient may register complete radiotherapy long anticipated s/he complete least 45 Gy ) . Eligible plan receive maintenance temozolomide completion definitive radiotherapy plus temozolomide . Willing remain abstinent consume alcohol disulfiram . Meets follow laboratory criterion : Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin &gt; 9.0 g/dL ( transfusion and/or ESA allow ) Total bilirubin ≤ 2x institutional upper limit normal ( ULN ) AST ALT &lt; 3 x ULN Calculated creatinine clearance must &gt; 60 mL/min ( CockcroftGault ) Females childbearing potential ( defined female nonmenopausal surgically sterilize ) must willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Able take oral medication . Able understand willing sign IRBapproved write informed consent document ( legally authorize representative permit ) . Receipt investigational agent within 14 day prior study enrollment . Enrolled another clinical trial test novel therapy drug . History allergic reaction disulfiram . Treatment clinically significant cytochrome P450 enzyme inducer , phenytoin , phenobarbital , chlordiazepoxide , diazepam , isoniazid , metronidazole , warfarin , amitriptyline within 14 day prior first dose disulfiram . Of note , lorazepam oxazepam affect P450 system contraindicate disulfiram . Active severe hepatic , cardiovascular , cerebrovascular disease , include myocardial infarction within 6 month prior enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Appendix B ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . History idiopathic seizure disorder , psychosis schizophrenia . Pregnant and/or breastfeeding . Women childbearing potential must negative pregnancy test within 14 day initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>